Relationship between phosphodiesterase type 4 inhibition and anti-inflammatory activity of CI-1044 in rat airways

Fundamental and Clinical Pharmacology

Volumn 24, Issue 1, 2010, Pages 73-82

  Pruniaux, Marie Pierre ^a   Lagente, Vincent ^b   Ouaged, Malika ^a   Bertin, Bernadette ^a   Moreau, François ^a   Julien Larose, Christine ^a   Rocher, Marie Noelle ^a   Leportier, Christelle ^a   Martin, Brigitte ^a   Bouget, Anita ^a   Dubuit, Jean Pierre ^a   Burnouf, Catherine ^a   Doherty, Annette M ^a   Bertrand, Claude P ^a  

^a PFIZER INC   (United States)

^b UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Asthma; Chronic obstructive pulmonary disease; Inflammation; Phosphodiesterase; Tumor necrosis factor

Indexed keywords

ANTIINFLAMMATORY AGENT; CI 1044; CILOMILAST; LIPOPOLYSACCHARIDE; N (9 AMINO 3,4,6,7 TETRAHYDRO 4 OXO 1 PHENYLPYRROLO[3.2.1 J,K][1,4]BENZODIAZEPIN 3 YL) 3 PYRIDINECARBOXAMIDE; OVALBUMIN; PHOSPHODIESTERASE 4A5; PHOSPHODIESTERASE 4B2; PHOSPHODIESTERASE 4C2; PHOSPHODIESTERASE 4D3; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE V; PHOSPHODIESTERASE VII; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AIRWAY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BROWN NORWAY RAT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; EX VIVO STUDY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INFLAMMATORY CELL; LOEFFLER PNEUMONIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANIMALS; AZEPINES; CARBOXYLIC ACIDS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; INFLAMMATION; INHIBITORY CONCENTRATION 50; LIPOPOLYSACCHARIDES; MALE; NIACINAMIDE; NITRILES; PHOSPHODIESTERASE INHIBITORS; PULMONARY EOSINOPHILIA; RATS; RATS, INBRED BN; ROLIPRAM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 74049105158     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2009.00725.x     Document Type: Article

References (26)

1. Torphy T.J. Phosphodiesterase isoenzymes. Molecular targets for novel antiasthma agents. Am. J. Resp. Crit. Care Med. (1998) 157 351 370.
2. Lanfear J., Robas N.M. Mammalian cyclic nucleotide phosphodiesterases and their cDNA sequences. Eur. Pat. Appl. (1999) EP 967284 A1.
3. Burnouf C., Pruniaux M.P. Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs. Curr. Pharm. Des. (2002) 8 1255 1296.
4. Spina D. PDE4 inhibitors: current status. Br. J. Pharmacol. (2008) 155 308 315.
5. Barnes P.J. Cyclic nucleotides and phosphodiesterases and airway function. Eur. Respir. J. (1995) 8 457 462.
6. Chung K.F. Phosphodiesterase inhibitors in airways disease. Eur. J. Pharmacol. (2006) 533 110 117.
7. Barnes P.J. The cytokine network in asthma and chronic obstructive pulmonary disease. J. Clin. Invest. (2008) 118 3546 3556.
8. Giembycz M.A. Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here? Drugs (2000) 59 193 212.
9. Compton C.H., Gubb J., Nieman R., et al. International Study Group. Cilomilast efficacy in a 12-month study of patient with asthma. Am. J. Resp. Crit. Care Med. (2000) 161 A505.
10. Compton C.H., Gubb J., Nieman R., et al. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomized, dose-ranging study. Lancet (2001) 358 265 270.
11. Timmer W., Leclerc V., Birraux G., et al. The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo. J. Clin. Pharmacol. (2002) 42 297 303.
12. Rabe K.F., Bateman E.D., O'Donnell D., Witte S., Bredenbröker D., Bethke T.D. Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (2005) 366 563 571.
13. Thompson J.W., Teraski W.L., Epstein P.M., Strada S.J. Assay of nucleotide phosphodiesterase and resolution of multiple molecular forms of the isoenzyme. Adv. Cycl. Nucleotide Res. (1979) 10 69 92.
14. Thompson J.W., Appleman M.M. Multiple cyclic nucleotide phosphodiesterase activities in rat brain. Biochemistry (1971) 10 311 316.
15. Lavan B.E., Lakey T., Houslay M.D. Resolution of soluble cyclic nucleotide phosphodiesterase isoenzymes, from liver and hepatocytes, identifies a novel IBMX-insensitive form. Biochem. Pharmacol. (1989) 38 4123 4136.
16. Elwood W., Sun J., Barnes P.J., Giembycz M.A., Chung K.F. Inhibition of allergen-induced lung eosinophilia by type-III and combined type III- and IV-selective phosphodiesterase inhibitors in Brown-Norway rats. Inflamm. Res. (1995) 44 83 86.
17. Livi G.P., Kmetz P., McHale M.M., et al. Cloning and expression of cDNA for a human low-Km, rolipram-sensitive cyclic AMP phosphodiesterase. Mol. Cell Biol. (1990) 10 2678 2686.
18. Bolger G.B., Rodgers L., Riggs M. Differential CNS expression of alternative mRNA isoforms of the mammalian genes encoding cAMP-specific phosphodiesterases. Gene (1994) 149 237 244.
19. Engels P., Abdel'Al S., Hulley P., Lübbert H. Brain distribution of four rat homologues of the Drosophila dunce cAMP phosphodiesterase. J. Neurosci. Res. (1995) 41 169 178.
20. Burnouf C., Auclair E., Avenel N., et al. Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1- phenyl-3,4,6,7-tetrahydro[1,4] diazepino[6,7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors. J. Med. Chem. (2000) 43 4850 4867.
21. Barnette M.S., Christensen S.B., Essayan D.M., et al. SB 207499 (Cilomilast), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J. Pharmacol. Exp. Ther. (1998) 284 420 426.
22. Prabhakar U., Lipshutz D., Bartus J.O., et al. Characterisation of cAMP-dependant inhibiton of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int. J. Immunopharmacol. (1994) 16 805 816.
23. Cheng J.B., Watson J.W., Pazoles C.J., et al. The phosphodiesterase type 4 (PDE4) inhibitor CP-80,633 elevates plasma cyclic AMP levels and decreases tumor necrosis factor-α (TNFα) production in mice: effect of adrenalectomy. J. Pharmacol. Exp. Ther. (1997) 280 621 626.
24. Brideau C., Van Staden C., Styhler A., Rodger I.W., Chan C.C. The effects of PDE4 inhibitors on tumour necrosis factor-αand leukotriene B4 in a novel human whole blood assay. Br. J. Pharmacol. (1999) 126 979 988.
25. Torphy T.J., Zhou H.Z., Cieslinski L.B. Stimulation of beta-adrenoceptors in a human monocyte cell line (U937) upregulates cyclic AMP (specific phosphodiesterase activity. J. Pharmacol. Exp. Ther. (1992) 263 1195 1205.
26. Griswold D.E., Webb E.F., Badger A.M., et al. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo. J. Pharmacol. Exp. Ther. (1998) 287 705 711.